Replies to post #150628 on Biotech Values

[DewDiligence]

If a treatment-naive patient fails a nuke/NS5A combo, it's safe to say they can be retreated in the future with a nuke/P.I. without concerns over class resistance.

At worst, a patient who fails ABT’s 5-drug regimen could be retreated with an interferon/nuke-based regimen, but there will likely be other (more attractive options) too.